CDKN2A and glioblastoma: To elucidate the in vivo role of P16INK4A+ SnCs in GBM progression, we generated a CDKN2A‐DTR (CDKN2A‐Luc‐tdTomato‐CreERT2+/‐; Rosa26‐LSL‐iDTR+/‐) mouse model to identify, track, and selectively kill P16INK4A+ SnCs in vivo (Figure2A,B).